vimarsana.com

இல்லுமின இணைக்கப்பட்டுள்ளது பகுப்பாய்வு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

2 Stocks That Wall Street Hates but You ll Probably Like

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights For good or bad, what Wall Street analysts think about a stock makes a big difference. One downgrade from an analyst can cause a stock to sink. On the other hand, an analyst s upgrade or price target increase usually provides a nice positive catalyst for a stock. But you might need to sit down for this Wall Street analysts aren t always right. That s shocking, I know. And sometimes they can be flat-out wrong about a stock. With that in mind, here are two stocks that Wall Street hates but you ll probably like.

New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale

New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale Illumina, Inc. (NASDAQ: ILMN) is transforming genomic data bottlenecks into catalysts with the launch of Illumina Connected Analytics (ICA). This new and integrated bioinformatics solution provides a comprehensive, private, cloud-based data platform that empowers customers to manage, analyze, and explore large volumes of multi-omic data in a secure, scalable, and flexible environment. Illumina Connected Analytics has appeared at a critical time for our research groupjust as our analysis needs have started exceeding our existing capability, noted Dan Spiegelman from Montreal Neurological Institute and Hospital in Canada. The scalability of the joint genotyping tools has enabled us to perform analyses larger than any we have attempted before, in a surprisingly short timeframe. This platform not only meets our current needs but will all

Illumina to launch cloud-based multi-omics analysis platform

Product News: New bioinformatics solution powers multi-omics discovery at massive scale 12 Jan 2021 Illumina is transforming genomic data bottlenecks into catalysts with the launch of Illumina Connected Analytics (ICA). This new and integrated bioinformatics solution provides a comprehensive, private, cloud-based data platform that empowers customers to manage, analyze, and explore large volumes of multi-omic data in a secure, scalable, and flexible environment. “Illumina Connected Analytics has appeared at a critical time for our research group just as our analysis needs have started exceeding our existing capability,” noted Dan Spiegelman from Montreal Neurological Institute and Hospital in Canada. “The scalability of the joint genotyping tools has enabled us to perform analyses larger than any we have attempted before, in a surprisingly short timeframe. This platform not only meets our current needs but will allow us room to grow our analyses to petabase scale.”

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.